Hepatitis C Virus

Xi'an Jiao Tong University, Medical Department details research in hepatitis C virus

Published in Hepatitis Weekly, August 11th, 2008

"For chronic hepatitis C virus (HCV) infection, the effects of current therapies are limited. To evaluate the efficacy and safety of the interferon beta-1a (IFN beta-1a) versus IFN beta-1a plus ribavirin (RBV) combination on Chinese treatment-naive patients with chronic hepatitis C, a randomized, placebo-controlled study was performed," scientists writing in the journal Digestive Diseases and Sciences report.

"A total of 26 naive patients histologically confirmed to have chronic hepatitis C were double-blindly and randomly assigned to receive either IFN beta-1a 44 mu g (12 MIU) (IFN beta-1a group) or placebo (placebo group) three times per week for 12 weeks. At...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2008-08-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry